Arena Pharma (ARNA) Shares Now Up ~130% Since Positive FDA Panel Vote on Lorcaserin
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals (Nasdaq: ARNA) shares are continuing higher Wednesday as investors continue to anticipate a good outcome from its scheduled PDUFA on June 27th for its proposed weight-loss drug lorcaserin.
Shares are up 136 percent following a positive FDA advisory panel vote made on May 10th.
The Stock is up an additional 8.8 percent Wednesday.
Shares are up 136 percent following a positive FDA advisory panel vote made on May 10th.
The Stock is up an additional 8.8 percent Wednesday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Cardinal Health (CAH) shares down after losing OptumRx contracts
- Texas Instruments (TXN) jumps on first above-consensus guide in seven years
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
